NO985956L - Mixture for improved uptake of polar drugs from mucosal surfaces - Google Patents

Mixture for improved uptake of polar drugs from mucosal surfaces

Info

Publication number
NO985956L
NO985956L NO985956A NO985956A NO985956L NO 985956 L NO985956 L NO 985956L NO 985956 A NO985956 A NO 985956A NO 985956 A NO985956 A NO 985956A NO 985956 L NO985956 L NO 985956L
Authority
NO
Norway
Prior art keywords
mixture
mucosal surfaces
improved uptake
polar drugs
metabolizable
Prior art date
Application number
NO985956A
Other languages
Norwegian (no)
Other versions
NO985956D0 (en
Inventor
Lisbeth Illum
Peter James Watts
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO985956L publication Critical patent/NO985956L/en
Publication of NO985956D0 publication Critical patent/NO985956D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Blanding for administrasjon til en mukosal overflate hos et pattedyr, omfattende en ikke-metaboliserbar gallesalt analog og en terapeutisk forbindelse. Den ikke-metaboli- serbare gallesalt-analogen er fortrinnsvis en forbindelse av cholin og ei aminosyre som ikke forekommer naturlig, spesielt cholylsarkosin. Den terapeutiske forbindelsen er fortrinnsvis et polart molekyl.A composition for administration to a mucosal surface of a mammal comprising a non-metabolizable bile salt analogue and a therapeutic compound. The non-metabolizable bile salt analogue is preferably a compound of choline and an amino acid that does not occur naturally, especially cholylsarcosine. The therapeutic compound is preferably a polar molecule.

NO985956A 1996-07-06 1998-12-18 Mixture for improved uptake of polar drugs from mucosal surfaces NO985956D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
PCT/GB1997/001852 WO1998001159A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (2)

Publication Number Publication Date
NO985956L true NO985956L (en) 1998-12-18
NO985956D0 NO985956D0 (en) 1998-12-18

Family

ID=10796483

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985956A NO985956D0 (en) 1996-07-06 1998-12-18 Mixture for improved uptake of polar drugs from mucosal surfaces

Country Status (8)

Country Link
EP (1) EP0993305A2 (en)
JP (1) JP2000515503A (en)
KR (1) KR20000023583A (en)
AU (1) AU722724B2 (en)
CA (1) CA2257563A1 (en)
GB (2) GB9614235D0 (en)
NO (1) NO985956D0 (en)
WO (1) WO1998001159A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
ATE386508T1 (en) * 1999-02-22 2008-03-15 Merrion Res I Ltd SOLID ORAL DOSAGE FORM CONTAINING AN ABSORPTION ENHANCER
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US20060019872A1 (en) * 2002-12-11 2006-01-26 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
DE102004027924A1 (en) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Pharmaceutical form containing the active ingredient cholylsarcosine
EP2526950A1 (en) 2006-04-07 2012-11-28 Merrion Research III Limited Solid oral dosage form containing an enhancer
KR20110007614A (en) 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 Compositions of gnrh related compounds and processes of preparation
PL3679941T3 (en) 2009-06-18 2023-04-17 Serenity Pharmaceuticals Llc Safe desmopressin administration
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CN103476419A (en) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 Pharmaceutical compositions of iron for oral administration
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN108201531A (en) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
PL176317B1 (en) * 1993-06-29 1999-05-31 Ferring Bv Preparation for intrarhinal administration of desmopressin
JPH11292787A (en) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd Transucosal preparation containing physiologically active peptide

Also Published As

Publication number Publication date
AU722724B2 (en) 2000-08-10
KR20000023583A (en) 2000-04-25
AU3453997A (en) 1998-02-02
NO985956D0 (en) 1998-12-18
CA2257563A1 (en) 1998-01-15
WO1998001159A3 (en) 1998-03-26
GB9900050D0 (en) 1999-02-24
GB2330533B (en) 2000-10-25
GB9614235D0 (en) 1996-09-04
WO1998001159A2 (en) 1998-01-15
EP0993305A2 (en) 2000-04-19
JP2000515503A (en) 2000-11-21
GB2330533A (en) 1999-04-28

Similar Documents

Publication Publication Date Title
NO985956L (en) Mixture for improved uptake of polar drugs from mucosal surfaces
PT951474E (en) NEW DERIVATIVES OF CICLOSPORIN ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PT1115417E (en) USING DAPTOMYCIN
EA199900937A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VORIKONAZOL
NO971889D0 (en) Compounds and compositions for delivery of active agents
BR9810312A (en) Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
PT948527E (en) NEW CYCLOSPORAN DERIVATIVES HIS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
DE69727956D1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING BREATHING DEPRESSIONS
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
DE69837324D1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY USING COPOLYMER-1
HUP0302635A2 (en) Phospholipid derivatives of valproic acid and mixtures thereof
NO20015931L (en) Pharmaceutical formulations and methods comprising intranasal morphine
ES2033985T3 (en) A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION.
LV12291A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity
DK0796622T3 (en) Use of a gonadotropin-releasing hormone analogue or mimic thereof for the preparation of a pharmaceutical composition as an adjunct to the invasive treatment of carcinomas
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
BR9813319A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections and for preparing a compound
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
HK1024164A1 (en) Use of composition and a cosmetic method for reducing or preventing stinging
BG97123A (en) DERIVATIVES OF HUMAN BILE SALTS, LIPASE AND PHARMACEUTICAL COMPOSITIONS BASED THEREOF
FR2690847B1 (en) COMPOSITIONS WITH AGONIST ACTIVITY OF SELECTIVE 5HT1 ANALOGUE RECEPTORS.
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
BR9911756A (en) Compound, use of a growth hormone secretagogue or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method to stimulate the release of growth hormone by a mammal's pituitary, and use of a compound
NO952987L (en) Wound healing mixture
AR008245A1 (en) DERIVATIVES OF ACETIC ACID, USE OF THE SAME IN THE MANUFACTURE OF A THERAPEUTIC AGENT AND PROCESS TO PREPARE SUCH DERIVATIVES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application